Kiara Nazon

Discussions with government officials about timely access to care and treatment for people living with arthritis (including pharmacare, addressing wait times, models of care, and pain management). Excise Tax Act, specifically with respect to the application of sales tax on medical cannabis Discussions with government officials with respect to policy and regulation of medical cannabis. Discussions with government about strategies and supports to help improve quality of life for people living with arthritis. Advocate for increased government funding for research, innovation and data related to arthritis and to support patient oriented research. Government support for health charities.

Seek increased funding for type 1 diabetes research Discussions and information sharing on improving regulatory pathways for cell and gene therapy Discussions and information sharing around: Procurement and tariffs impact Insulin production Stock piles To seek funding to expand the foundation's educational program to raise awarenes of type 1 diabetes and diabetes management in Canada. Ensuring Bill C-64, the National Pharmacare Act, meets the needs of Canadians living with type 1 diabetes by having adequate insulin and diabetes devices coverage, while respecting patient choice. Seek an increase funding for the Canadian Clinical Trial Network to find a cure for Type 1 Diabetes (T1D). Ongoing conversation with Health Minister's Office regarding JDRF-CIHR Partnership to Defeat Diabetes renewal funding. Meeting with Juvenile Diabetes Caucus Co-Chairs to discuss strategies and tactics to move JDRF Canada Pre-Budget Submission priorities forward including additional funding for research towards a cure for type 1 diabetes Canadian Institutes of Health Research (CIHR) and the Strategy for Patient-Orientated Research (SPOR) Discussions with CIHR and SPOR Network about collaboration towards the creation of a type 1 diabètes registry

Assist CanFASD in advocating for the development of a National FASD Strategy.

Educating elected officials and civil servants about the benefits of the "In Motion & Momentum +" program to prepare underserved populations for success in the workforce and in training programs.

Clean electricity regulations and emissions cap Investing in Employment Insurance, care workers, unionized jobs and strong workplace standards Addressing the high cost of living and investing in affordable housing Implementation of universal pharmacare, dental care, long term care and mental health care Labour provisions in the Canada-Ecuador Trade Agreement and Canada-United States-Mexico Agreement. The regularization of undocumented workers, update and possible next steps for the CLC Out-of-status Construction Workers in the GTA project Bill C-65, Canada Elections Act With interest in provisions that impact Third Parties and contributions to Third Parties Bill C-27, Digitial Charter Implementation Act - Part III of C-27 and the impact of artificial intelligence on jobs and workers.

Value for physiotherapy in diverse sectors such as primary care. Discussion includes physiotherapy access, expansion of services and scope of practice. Scope of Practice: Physiotherapy scope of practice, skill-set optimization, value for physiotherapy, economic impact. Raise awareness about the role of physiotherapy within a multidisciplinary approach to healthcare and educate policymakers on how physiotherapy can help reduce healthcare costs, maximize current spending and funding allocation through physiotherapy skill optimization, support preventative care and contribute to a healthier Canadian population at all stages of life. Internationally Educated Health Professionals: Monitoring issues related to emerging needs of profession and population. Improving access to safe and effective pain management, such as physiotherapy as a non-pharmacological care, as an upstream and early intervention and prevention response to the opioid crisis Health Human Resource Strategy: Explore opportunities to develop health human resource strategy for the profession of physiotherapy. Discussion includes health human resources planning, health human resource crisis, workforce planning, workforce shortages, scope of practice. Enable support and funding for those communities that could potentially benefit most from telerehabilitation and virtual services, including Indigenous, First Nations, Inuit and Metis and rural and remote populations, where infrastructure may presently exclude them from access (no cellular or internet service/access). Discussion on equity of access to physiotherapy services. Caseload Guidelines: Joint application for funding from Health Canada for Caseload Guidelines development for Physiotherapy, Occupational Therapy. and Speech Language Pathology. Including research regarding physiotherapy specific caseload guidelines. Adult physiotherapy services covered under the Non-Insured Health Benefits program. This includes NHIB, orthotics, medical devices, coverage.

Regulations, policies and programs related to the reimbursement recommendations decision-making process and framework done by the Canadian Agency for Drugs and Technologies in Health (CADTH)/Common Drug Review as well as the review times and processes conducted by Health Canada for the purpose of obtaining a notice of compliance. National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathways for drugs for rare diseases and the government strategy. Monitoring and engaging the Government and Parliamentarians on policies and programs that would provide greater clarity and predictability in the tax outcomes and improvements to tax measures such as the Manufacturing & Processing (M&P) credit and the Scientific Research & Developmental (SR&ED). Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework. Federal Public Drug Plans, with respect to the reimbursement of therapeutic products for Federal plan beneficiaries Policies related to the National Strategy for Drugs for Rare Disease as it relates to separate regulatory pathway for drugs for rare diseases and the government strategy. Policies related to Subsequent Entry Biologics (SEBs) pertaining to Draft Guidance for Sponsors; Information and Submission requirements for SEBs, regulations and intellectual property policies, naming conventions Monitoring and engaging on the Government’s commitment (Budget, SFT, Fall Economic Update) to create a national strategy for drugs for rare diseases; create a new Canadian Drug Agency; and the implementation of national, universal pharmacare. Pharmaceutical policy and any negotiations of a Health Accord or agreement with the Provinces/Territories, as it relates to National Pharmacare/universal or catastrophic drug coverage, Drug policies & Pricing. The Department of Innovation, Science and Economic Development and the Innovation Agenda for the life sciences sector: policy or program initiatives to support life science research and development conducted in Canada and manufacturing capability, and as it relates to Canada’s Biomanufacturing and Life Sciences Strategy. Monitoring and engaging the Government and Parliamentarians on policies and programs related to Canada's biomanufacturing and life sciences sector strategy National Pharmacare (Bill C-64, An Act respecting pharmacare) Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies. Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products. Income Tax Act as it relates to biopharmaceutical industry. Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy. Discussions around the World Trade Organization consideration of a TRIPS Patent Waiver - Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". The Food and Drugs Act, or the Export and Imports Permits Act (Export Control List) or any other legislative and regulatory means in order to protect the Canadian supply of drugs in light of importation legislation in the United States. Standing Committee on Finance (FINA) as it relates to pre-budget consultations. Pharmaceutical intellectual property protection as it relates to international trade agreements Patent Act and Patented Medicines (Notice of Compliance) Regulations, as it relates to the regulation of intellectual property, approval for therapeutic products, changes to modernize the Right of Appeal House of Commons Standing Committee of Science and Research (SRSR) as it relates to Science in Canada and/or any other pertinent legislative proposal before the committee House of Commons Standing Committee of Industry and Technology (INDU) as it

Communications with Federal Government officials regarding the elimination of child labour in Canada's supply chains. UNICEF Canada seeks and obtains contributions from Global Affairs Canada for international assistance programming. Communications with Government Officials to build support for increased Canadian investment and leadership in regards to children's health, nutrition, education, protection and participation, including the most vulnerable children such as those facing gender-based discrimination, conflict, and displacement. Communications with Federal Government officials regarding with respect to our international development programs. Communications with Federal Government officials regarding child rights policy in Canada.

Watch for any incoming regulation on updating privacy legislation and new e-commerce legislation to ensure company is aligned Explore and understand the impact of C-11, Amendments to the Broadcasting Act, to the arts and culture and media space